Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 6/20 | 0.51 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | BCL9 | O00512 | 2/20 | 0.37 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23639065 | 1.00 | SCN9A (0.51) | SCN9AHCRTR2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL23141079 | 0.88 | SCN9A (0.53) | SCN9AHCRTR2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL20073015 | 0.87 | SCN9A (0.49) | SCN9AHCRTR2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL20063933 | 0.87 | SCN9A (0.49) | SCN9AHCRTR2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL21306610 | 0.87 | SCN9A (0.49) | SCN9AHCRTR2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL23639040 | 0.84 | TAS1R3 (0.44) | SCN9AHCRTR2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL31433355 | 0.84 | TAS1R3 (0.44) | SCN9AHCRTR2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL23638941 | 0.82 | SCN9A (0.52) | SCN9AHCRTR2DPP4BCL9CTNNB1 | |
| SCHEMBL23140784 | 0.78 | SCN9A (0.47) | SCN9AHCRTR2MGLLNOTUM | |
| SCHEMBL21384745 | 0.74 | PDE4B (0.53) | BCL9CTNNB1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115576-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-12209075-B2 | Pyridine-sulfonamide derivatives as sodium channel inhibitors | GENENTECH, INC. (US) | 2025-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209075-B2 | Pyridine-sulfonamide derivatives as sodium channel inhibitors | SCN1B, CACNA1A, SCN1A | SCN9A 36/4885HCRTR2 1445/4885TAS1R3 254/4885 |
| US-20250115576-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | F12, REN, ZYX | SCN9A 1485/4885HCRTR2 252/4885TAS1R3 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.